The Indian Pharmacopoeia Commission (IPC), an autonomous body under the Ministry of Health and Family Welfare, organised a scientific conclave on Indian Pharmacopoeia (IP) 2026 in Haridwar on 11 June 2026. The event aimed to create awareness about the new provisions of IP 2026 and to promote pharmacopoeial standards across the pharmaceutical sector.
Key Developments
- Inaugural address by Shri Sandeep Jain, Chairman of the Association of Devbhumi Pharma Industries (ADPI), stressed the need for close collaboration between industry and standard‑setting bodies.
- Speeches by Shri Sidharth Sahai Malhotra, Assistant Drugs Controller (India), CDSCO, and Shri Tajber Singh, Drug Controller, State Licensing Authority, Uttarakhand, highlighted the role of pharmacopoeial standards in ensuring regulatory compliance and public‑health safety.
- Chief Guest Dr. V. Kalaiselvan, Secretary‑cum‑Scientific Director of IPC, outlined the major advancements incorporated in IP 2026 and called for active industry participation to implement the standards effectively.
- Technical sessions covered recent updates on reference substances, microbiological quality requirements, quality management systems, analytical investigations and biological standards.
- An interactive Q&A allowed participants to seek clarifications from IPC scientists on technical, regulatory and implementation aspects of IP 2026.
Important Facts
- Uttarakhand is a leading pharmaceutical manufacturing hub and has effectively used the IP and Indian Pharmacopoeia Reference Substances to assure medicine quality.
- The conclave brought together manufacturers, quality‑control and quality‑assurance professionals, regulators, analytical scientists and drug‑testing laboratory personnel.
- IPC pledged continued capacity‑building and hand‑holding support to help manufacturers adopt the new standards.
UPSC Relevance
The event illustrates the institutional framework (IPC) governing drug quality in India, a topic covered under GS 3 (Health, Economy). Understanding the role of CDSCO and state licensing authorities links to GS 2 (Polity). The emphasis on quality compliance and ethical manufacturing ties into GS 4 (Ethics).
Way Forward
- IPC will expand awareness programmes and technical assistance for manufacturers across all states.
- State governments, especially in pharma clusters like Uttarakhand, should facilitate adoption of IP 2026 by integrating standards into licensing and inspection processes.
- Pharmaceutical companies need to strengthen their quality management systems and invest in training for analytical and microbiological testing.
- Continuous dialogue among regulators, industry bodies and scientific experts is essential to maintain high standards of drug safety and to support India’s ambition as a global pharmaceutical leader.